Lipid nanoparticles (LNPs) act as carriers for mRNA and CRISPR payloads across a wide range of therapeutic applications, from cancer to inflammatory and genetic diseases. The same delivery system used ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a result—a condition that impacts 6.8 million Americans and carries a high ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death. The agency has ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, Morgan Stanley lifted the price target on CRISPR Therapeutics AG ...

One year ago, a baby from Delaware County, Pennsylvania, became the first person in the world to receive a new revolutionary therapy at Children's Hospital of Philadelphia. "We didn't know that we ...

CNBC's Becky Quick reports on the progress of KJ Muldoon, the first patient to receive a personalized CRISPR-based gene editing therapy. Got a confidential news tip? We want to hear from you. Sign up ...

Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding. The stock requires patience, but there is a visible path to a bright future.

Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...

CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient ...

Gene editing is a numbers game. For any genetic tweaks to have notable impact, a sufficient number of targeted cells need to have the disease-causing gene deleted or replaced. Despite a growing ...

Time-restricted feeding (TRF) significantly reduces symptomatic disease activity and systemic inflammation in adults with Crohn’s disease and overweight or obesity, according to new research. In a ...

A genetics‑guided small molecule called compound 6 gently turns down an overactive immune pathway (CARD9), offering a more precise, durable, and potentially safer treatment strategy for Crohn’s ...